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Abstract

Author Manuscript

Evidence strongly supports that access to specialty gastroenterology or hepatology care in
cirrhosis is associated with higher adherence to guideline-recommended care and improves clinical
outcomes. Presently, only about one half of acute care hospitalizations for cirrhosis-related
complications result in inpatient specialty care and the current hepatology workforce cannot meet
the demand of patients with liver disease nationwide, particularly in less densely populated areas
and in community-based practices not affiliated with academic centers. Telemedicine, defined as
the delivery of health care services at a distance using electronic means for diagnosis and
treatment, holds tremendous promise to increase access to broadly specialty care. The technology
is cheap and easy to use, however, is presently limited in scale by interstate licensing restrictions
and reimbursement barriers. The outbreak of severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) and Coronavirus Disease 2019 (COVID-19) has, in the short-term, accelerated the
growth of telemedicine delivery as a public health and social distancing measure. Herein, we
examine whether this public health crisis can accelerate the national conversation about broader
adoption of telemedicine for routine medical care in non-crisis situations using a case series from
our telehepatology program as a pragmatic example.
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The outbreak of SARS-CoV-2 Coronavirus Disease 2019 (COVID-19), which began in
December 2019 has been declared a public health emergency by the Department of Health
and Human Services.(1) Widespread transmission of the virus has reached pandemic
proportions and is now beginning to cause disruptions in daily life in the United States. As
part of the public health response, the Center for Medicare & Medicaid Services (CMS) and
private payers are lifting restrictions on telemedicine reimbursement to facilitate healthcare
access while minimizing the spread of infection. As part of a social distancing and
containment strategy, multiple experts and tertiary care centers are rapidly adopting
telephone- and video-based appointments to assist with triage of symptomatic patients and
conduct routine visits to prevent the spread of infection. This crisis situation, however,
additionally presents an opportunity to more broadly examine telemedicine, its promise and
barriers to implementation.

Author Manuscript

Telemedicine, a term often used interchangeably with telehealth, is defined as the delivery of
health care services at a distance using electronic means for “the diagnosis of, treatment, and
prevention of disease and injuries, research and evaluation, education of health care
providers” to improve health.(2) Despite the potential of telemedicine to improve access to
care, its uptake has been variable due to inadequate reimbursement, interstate licensing
barriers, and to a lesser extent lack of infrastructure and resistance to change. (2, 3) We
describe a case study of a “telehepatology” (telemedicine for advanced liver disease)
between a tertiary-care center and community-based gastroenterology practice, its success
and challenges, in order to help inform a conversation about its utility in a public health
crisis and beyond.

TELEHEPATOLOGY PROGRAM
Author Manuscript

Background

Author Manuscript

In the Fall of 2017, our team embarked upon a project with the Penn Medicine Center for
Health Care Innovation seeking to improve access to liver disease specialists by leveraging
telemedicine for patients with advanced liver disease. The motivating factor to use
telemedicine as the care delivery innovation was that there is a dearth of liver disease
specialists nationally with the majority concentrated in heavily populated urban areas and
transplant centers.(4, 5) Multiple studies in liver disease have shown that access to specialty
care improves adherence to guideline-recommended care for liver disease and clinical
outcomes such as readmissions and mortality.(6-8) Rooted in this prior research, the goal of
our program was to improve access to care for advanced liver disease, which has a
comparable morbidity and mortality to end stage congestive heart failure and chronic
obstructive pulmonary disease.(9)
The tertiary care team partnered with a large, community-based gastroenterology (GI)
practice of 23 healthcare providers located in Lancaster, Pennsylvania about 60 miles from
the downtown University Hospital. Serendipitously, a physician who cared for many of the
complex liver disease cases retired from the community-based GI practice as the partnership
began, and so the case for the telemedicine program was based on the mutual desire for
innovation, efficiency, and clinical need. Due to the lack of reimbursement parity by most
commercial payers in Pennsylvania, the service was provided on a one-time basis “in-kind”
Hepatology. Author manuscript; available in PMC 2020 September 11.
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under a research grant. Patients were not billed for the service and providers were not
reimbursed.
Project Set-Up and Execution
After several planning phone calls, in-person meetings, and staff introductions,
VidyoConnect™ was installed at the referring site (Lancaster Pennsylvania) and tertiary care
site (Philadelphia Pennsylvania). The University hospital has a license for the technology,
which is HIPAA compliant and encrypted. The staff training was seamless, and the
scheduling workflows were developed within 2 weeks. The technology startup costs for the
clinical departments were minimal – two extra monitors, two cameras, two microphones, a
small amount of overhead, and scheduling staff time.
Objectives

Author Manuscript

The immediate goals of the project were to assess program feasibility as measured by the
team’s ability to deliver live video visits at a distance, acceptability for patients and
providers, and fidelity, i.e. was the program delivered as originally intended. The ultimate
goal was to develop a scalable and sustainable program to improve patient access to
subspecialty care for liver disease without compromising the quality of clinical care.
Workflow

Author Manuscript

All telehepatology program participants were established patients in the referring
community-based practice located about 60 miles from Philadelphia. The patients were
identified in two ways: 1) if they had a hospitalization for decompensated cirrhosis and were
offered a post-hospitalization telehepatology appointment, 2) if they were referred by their
gastroenterologist for a second opinion for the diagnosis of or management of any liver
disease. This was a pragmatic study whereby the hepatology consultant delivered
telemedicine to any patient determined to be clinically appropriate by the referring
community-based practice and were sequentially included. Patients verbally consented to the
appointment and subsequently verbally consented to answering surveys.

Author Manuscript

The appointment process was simple: a hepatologist at the University Hospital site (MS)
received liver disease referrals and scheduled patients at a time convenient for them and for
the provider. The patient attended a scheduled appointment in the office of the referring
community-based GI practice in a dedicated clinic exam room. The hepatologist conducted
one live video visit using Vidyo™ desktop technology between the Penn Medicine and the
referring GI practice. The medical assistant at the referring site in Lancaster Pennsylvania
obtained patient vital signs and medications and recorded immediate or urgent physician
recommendations after the visit. As both practices use Epic MyChart with the
CareEverywhere interoperability options, clinical records from the distant site were readily
available to the hepatology provider prior to and during the appointment. All other routine
communication took place via letters sent by the specialist to the referring providers as
conducted in routine clinical care.
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Feasibility and Fidelity—From March 2018 through December 2019, a total of 67
patients were referred to the telehepatology program, 57 (85%) had clinical appointments, 5
(7%) had electronic consultations, and 4 (6%) patients were not able to be scheduled due to
patient preferences or clinical issues. Patients were referred for 3 main reasons: 1) after a
cirrhosis-related hospitalization, 2) second opinion consultation on the clinical management
of advanced liver disease, 3) consideration of liver transplantation. The mean age was 52
(standard deviation 11.5), 27 (47%) were female; 26 (46%) had decompensated cirrhosis,
and 31 (54%) were referred for a second opinion for other diagnostic or treatment challenges
in liver disease. On average, the new patient visits lasted 31 minutes in-person with 30-45
minutes of reviewing patient records and charting before and after the visits. Two visits had
technical issues due to software upgrades resulting in one delayed visit on the same day and
one visit requiring rescheduling.
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Actionable Clinical Recommendations—A total of 26 (45%) individual patient visits
resulted in new tests being ordered, 26 (45%) resulted in medication changes, and 10 (18%)
led to subsequent liver transplant referrals. Among the 10 patients referred for
transplantation, 8 underwent subsequent liver transplant evaluation. Among those 8, 2 are
actively waitlisted, 3 have completed testing and are early for transplantation, 1 is in
evaluation, and 2 have been determined to not be transplant candidates.

Author Manuscript

Patient-Rated Acceptability—The team calculated a Net Promoter Score (NPS),
measuring patient likelihood to recommend the telehepatology service to a friend or
colleague, considered a gold standard customer satisfaction tool.(10) Patients were asked on
a scale of 0 to 10 to rate the likelihood of recommending the telemedicine service to a
colleague or friend. The NPS was then calculated as an index from −100 to 100. NPS above
70 indicates a very positive experience and a high likelihood of a positive word of mouth. A
total of 38 of 57 (65%)patients who had video appointments agreed to being contacted for
surveys and 37 of 38 (97%) of those contacted responded. Among the responders, the mean
NPS was 92, indicating they had an excellent experience and high satisfaction, well above
levels typically seen in health care settings. A total of 4 patients (11%) thought the
audiovisual quality of the video visit could be improved and 4 (11%) felt that provider
communication with referring providers could be improved.
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Provider-Rated Acceptability—Referring providers were asked to give verbal and
written open-ended feedback to study staff about their experience with the telemedicine
program. The feedback was uniformly positive, citing the hepatology provider as “excellent
to work with”, “helpful”, and “quick to provide recommendations and arrange for all of the
services that were needed to ensure a positive outcome”. The program was seen as
“convenient”, “seamless”, “helpful with difficult cases”, and “allowed us to obtain expert
consultation efficiently and quickly”. Another provider thought the telemedicine service was
“a valuable service to providers and the community”.
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The Challenge: How Can a Pilot Become a Program?
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Despite a highly efficient program with actionable clinical recommendations, high ratings
from patients and referring providers, and perceived benefit to the community, there are
multiple barriers in bringing the telehepatology pilot to scale.
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The key challenges are legislative barriers and payer variability. These are commonly interrelated: reimbursement is needed to financially support the program and at this time, payer
reimbursement policies are highly variable and most payers do not provide telemedicine
parity with in-person visits. In our state (Pennsylvania), there is limited reimbursement for
telemedicine in both rural and non-rural settings. Telemedicine programs cannot legally
provide “in-kind” new patient consultations, outside of the limited context of research, due
to the potential for referral inducement and the federal Anti-Kickback Statute, which
considers “in-kind visits” a form of referral inducement.(11) In the absence of payer
reimbursement, several different models of telemedicine would have been legal and
sustainable, however, not necessarily financially viable. The first model could have been a
‘physician to physician’ business agreement from the referring practice to the tertiary care
practice and the second ‘direct to consumer’ whereby the patient would pay a fee to the
referring provider. Both models were considered, but neither was deemed suitable or
financially sustainable by referring providers.
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Finally, our program is headquartered in a city, Philadelphia, in close proximity to a tri-state
area encompassing Pennsylvania, Delaware, and New Jersey. Unfortunately, the practice of
medicine and telemedicine being no exception is subject to state-specific licensing
regulations and cannot be delivered across state lines by a practitioner in Pennsylvania if
they are not licensed in those other states. State licensing laws were originally enacted to
prevent incompetent physicians from practicing and to control entry into the practice of
medicine in the Civil War Era. (12) However, these historical reasons for state licensing
restrictions are no longer valid and hamper providers’ ability to deliver care as they limit
patients’ ability to access it. These rules especially antiquated as medical licensing for
physicians must adhere to national clinical training standards and competencies set by the
Accreditation Council for Graduate Medical Education, the Centers for Medicare and
Medicaid Services’ Graduate Medical Education standards, and the Liaison Committee on
Medical Education. Licensing board exams are national and not state-specific. (13)
Unfortunately, telemedicine which in its promise is supposed to bridge distances and
improve access particularly suffers from the deleterious impact of these outdated laws.
Key Takeaways from the Local Pilot

Author Manuscript

After piloting the telehepatology program, there were multiple key takeaways imparted on
us by the experience. Firstly, partnerships between academic and community-based practices
are strengthened by increased communication and additional face-to-face time. By becoming
a virtual hepatology provider in a community-based clinic, the hepatologist was incorporated
into treatment team greatly facilitating open communication with medical assistants, nurses,
physicians, and advanced practice providers in the referring practice. These relationships
were built in a short period of time, and perhaps surprisingly did not require in-person
contact. Multiple patients remarked how thankful they were to receive an expert opinion

Hepatology. Author manuscript; available in PMC 2020 September 11.

Serper et al.

Page 6

Author Manuscript

whether it was reassurance or clinical concern resulting in further testing or transplant
evaluation. Referring providers felt the program was efficient and valuable, however, did not
see a business case for it that could help bring the program to scale in the current
reimbursement climate. Least expected, however, was the general lack of inertia when
piloting the new care delivery model. There was little hesitation on the part of our patients in
adopting a new way to communicate with a referring provider they had never met as long as
the procedure was explained to them ahead of the appointment. Perhaps, this reflects the
ubiquity of technology and enhanced uptake among all age groups.

Author Manuscript
Author Manuscript

The positive experience of our program must be placed into context as telemedicine for liver
disease has been successful in other healthcare settings, particularly in integrated systems of
care. Telemedicine has been successfully used for many years for Hepatitis C therapy in
incarcerated and rural populations.(2) One of the most durable and scalable examples of
telemedicine for liver disease has been for hepatitis C virus (HCV) treatment as part of the
Extension for Community Healthcare Outcomes (ECHO), or Project ECHO program.(14)
ECHO targets front-line primary care providers to enhance expertise and enable problembased learning via live video teleconferencing with subspecialty experts. Among other
factors, part of the success of Project ECHO is that it does not rely on billing or
reimbursement as a ‘provider-to-provider’ model. Innovative extensions of PROJECT
ECHO spearheaded by Price and colleagues, such as the University of California, San
Francisco’s ‘DeLIVER Care’ mobile HCV screening van equipped with point-of-care HCV
testing and liver stiffness assessment, have successfully expanded HCV care to the
community.(3) As an early adopter of telemedicine and after the success of Project ECHO in
2011, the Veteran Affairs developed and implemented the Specialty Care Access Network–
ECHO to increase access, training, and provide real-time expert consultation for primary
care physicians for multiple chronic conditions, including HCV and chronic liver disease.
Recent VA data from Su and colleagues support that the SCAN-ECHO program improves
survival in liver disease. (15) Several recent VA studies by Konjeti and John and colleagues
showed that telemedicine enhanced the efficiency of liver transplant evaluations. (16, 17)
Unfortunately, currently such programs cannot readily be implemented outside of integrated
systems of care or accountable care organizations given the regulatory and financial barriers
described above.
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We are now faced with a public health emergency due to the COVID-19 virus. Multiple
stakeholders are temporarily increasing telemedicine video visits in aiding symptom
screening and diagnosis in ways that are convenient, scalable and efficient. Although
convenience may sound simply like something that’s a nice bonus for the sake of
experience, however, we also know that eliminating friction and effort increase desirable
behaviors. For example, convenience may facilitate a patient with relevant symptoms and
health concerns seeking care earlier rather than putting it off and may lead to higher
engagement and better outcomes. Minimizing spread, based on human proximity and
contact, also reinforces telemedicine’s advantages for safety. Delivering urgent and routine
care for those who are infected and for populations who may be more vulnerable to
infection, such as the elderly or people who are immunocompromised, in a remote manner
limiting exposure frames this second layer of opportunity and simply makes common sense.
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The Current State of Telemedicine Emergency Coverage under COVID-19
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On February 28th, key telemedicine interest groups (The American Telemedicine
Association, eHealth Initiative, Health Innovation Alliance, Healthcare Information and
Management Systems Society (HIMSS), Personal Connected Health Alliance
(PCHAlliance) sent a letter to congress to expand access to telemedicine. (1) On March 4th,
2020 U.S. Congress approved an $8.3 billion package novel coronavirus (COVID-19)
spending package, which includes an emergency telehealth waiver allowing the Department
of Health and Human Services (DHHS) Secretary to waive certain Medicare telehealth
restrictions during the coronavirus public health emergency. (18) On March 24th, 2020, the
Coronavirus Preparedness and Response Supplemental Appropriations Act (H.R.6074) was
signed into law (19). This law temporarily lifts previous telehealth/telemedicine restrictions,
namely: 1) patients do not have live in rural areas to receive telemedicine, 2) there is no
restriction on the type of site where telemedicine can be delivered and patients may receive
telemedicine from home. HHS has issues a notice relaxing requirement to use Health
Insurance Portability and Accountability Act (HIPAA)-compliant software to communicate
with patients remotely as long as the technology is used in good faith. (18)
Following the passing of federal legislation, many private payers have lifted telemedicine
restrictions temporarily, made provisions for ‘parity’, i.e. the same levels of reimbursement
as for in-person visits, several have eliminated cost-sharing for telemedicine services.(20)
The legal and regulatory landscape continues to evolve rapidly with up-to-date federal and
state specific information on regulatory and billing compliance available on the websites for
the Department of Health and Human Services, (1), CMS (21), and the Center for Connected
Health Policy.(22)
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The Path Forward
Despite the promising developments to rapidly remove telemedicine barriers in addressing
the COVID-19 virus, multiple challenges remain when thinking about integrating
telemedicine into routine clinical care. Integrated health-systems such as the Veterans
Affairs and Kaiser have invested in telemedicine infrastructure, however, other healthsystems do not yet have the capability to bring these services to scale. Interstate licensing
issues and variable reimbursement policies will continue to be barriers before widespread
adoption will be possible as evidenced from our examples and many others that are
unpublished.

CONCLUSIONS
Author Manuscript

Telemedicine technology is low-cost, widely available, and accepted by patients and
providers. We highlight a case study in telehepatology whereby providing care to patients
with complex advanced liver disease is feasible, acceptable, efficient, and does not
compromise clinical care. The unprecedented COVID-19 public health emergency provides
us with an opportunity to leverage this technology not just in times of crisis, but to improve
access, safety and efficiency for primary and specialty care. In order to achieve this, we need
to change our payer reimbursement policies and inter-state licensing regulations to better
serve the healthcare needs of our community.
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COVID-19

Coronavirus Disease 2019

CMS

Centers for Medicare & Medicaid Services

ECHO

Extension for Community Healthcare Outcomes

HCV

Hepatitis C Virus

HHS

Health and Human Services

NPS

Net Promoter Score

SARS-CoV-2

severe acute respiratory syndrome coronavirus 2

SD

Standard Deviations
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